Please ensure Javascript is enabled for purposes of website accessibility

Weak Investor Sentiment Dooms Exact Sciences Corporation in January

By Sean Williams – Feb 5, 2016 at 3:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of Exact Sciences lost nearly 30% of their value in January, but new developments from the company were actually quite encouraging.

EXAS Chart

What: Shares of Exact Sciences (EXAS -2.74%), a molecular diagnostics company, were absolutely throttled in January, losing 29% according to data from S&P Capital IQ. The culprit behind the move? Look no further than weakening investor sentiment.

So what: In January the Nasdaq Biotechnology Index lost a whopping 21% of its value, and it dragged Big Pharma and diagnostics right down with it. What we witnessed from investors was a flight away from growth and risk and toward defensive investments and safety. This didn't mean that all drugmakers and diagnostic developers were off-limits, but those that are losing money got hammered.

In the case of Exact Sciences, the company has burned through $131 million in operating cash flow over the trailing 12-month period, and sales of its lead product, Cologuard, a diagnostic tool designed to noninvasively screen for colorectal cancer and advanced adenomas, have underperformed Wall Street's expectations. With volatility on the rise, companies that are losing money and projected to continue losing money for years to come are the easiest for investors to sell.

Lastly, it also doesn't help that Exact Sciences is one of the most short-sold stocks as a percentage of float. As of mid-January some 26.9 million shares were being held by short-sellers compared to a float of just 94.4 million. This demonstrates the amount of pessimism currently surrounding Exact Sciences.


Image source: Exact Sciences. 

Now what: Despite Exact Sciences' poor showing due to market uncertainty, the company actually had a pretty strong month when it came to new developments.

At the J.P. Morgan Healthcare Conference Exact Sciences offered guidance of 240,000 Cologuard screening tests in 2016 and between $90 million and $100 million in revenue, which is up in the neighborhood of 125% to 150% from 2015 levels. We also heard that 80% of Cologuard patients are currently being covered by Medicare, which is a good thing since it's being reimbursed at a rate of $509 per test.

Just days prior to the conference, Exact Sciences also announced an expanded agreement with Anthem (ELV -1.95%), the second-largest insurer in the U.S., to allow its Cologuard test to be a covered, in-network device in California. This latest agreement builds upon a prior agreement with Anthem from 2015, and the plan is to hopefully expand the test to some, or all, of the 13 states additional states that Anthem operates in.  

But, good developments aside, we'll want to see substantial improvements in Cologuard screening and insurance coverage in 2016 before giving the company a clean bill of health. It'll be some time before Exact Sciences is profitable, so these steps will go a long way to proving the staying power of this diagnostic test and Exact Sciences.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool recommends Anthem. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exact Sciences Corporation Stock Quote
Exact Sciences Corporation
EXAS
$33.41 (-2.74%) $0.94
Elevance Health Inc. Stock Quote
Elevance Health Inc.
ELV
$453.85 (-1.95%) $-9.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.